## 3 Results
### Patient Demographics and Distribution
\begin{table}
\begin{tabular}{c c c c} \hline  & **BCR (n = 20)** & **Non-BCR (n = 84)** & \(p\)**-Value** \\ \hline \multicolumn{4}{c}{**preoperative clinical characteristics**} \\ \hline Age (yr, range) \({}^{\dagger}\) & 70.5 (62–82) & 2.0 (52–83) & 0.911 \\ \hline PSA (ng/mL) \({}^{\dagger}\) & 14.8 (4.2–153.3) & 7.165 (2.7–426.6) & 0.031 \\ \hline Greatest percentage of biopsy core \({}^{\ddagger}\) & 64.0 (19–100) & 29.0 (1–100) & 0.000 \\ \hline Number of positive biopsy cores \({}^{\ddagger}\) & 6 (2–12) & 3 (1–12) & 0.000 \\ \hline SUP category and biopsy Gleason score & & & 0.034 \\ \hline
1, 6 (3 + 3) & 0 (0.0\%) & 13 (15.5\%) & \\ \hline
2, 7 (3 + 4) & 2 (10.0\%) & 17 (20.2\%) & \\ \hline
3, 7 (4 + 3) & 5 (25.0\%) & 29 (34.5\%) & \\ \hline
4, 8 & 8 (40.0\%) & 13 (15.5\%) & \\ \hline
5, 9–10 & 5 (25.0\%) & 12 (14.3\%) & \\ \hline \multicolumn{4}{c}{**preoperative imaging finding**} \\ \hline prostate volume at MRI (mL.) & 34.0 (24.0–93.6) & 40.4 (19.3–98.3) & 0.632 \\ \hline PIRADS & & & 0.029 \\ \hline
2 & 1 (5.0\%) & 9 (10.7\%) & \\ \hline
3 & 0 (0.0\%) & 18 (21.4\%) & \\ \hline
4 & 7 (35.0\%) & 32 (38.1\%) & \\ \hline
5 & 12 (60.0\%) & 25 (29.8\%) & \\ \hline Extracapsular extension at MRI & & & 0.001 \\ \hline negative & 7 (35.0\%) & 65 (77.4\%) & \\ \hline probable positive & 8 (40.0\%) & 13 (15.5\%) & \\ \hline positive & 5 (25.0\%) & 6 (7.1\%) & \\ \hline Seminal vessel invasion at MRI & & & 0.156 \\ \hline negative & 15 (75.0\%) & 75 (89.3\%) & \\ \hline probable positive & 5 (25.0\%) & 8 (9.5\%) & \\ \hline positive & 0 (0.0\%) & 1 (1.2\%) & \\ \hline \multicolumn{4}{c}{**postoperative parameters**} \\ \hline SUP category and surgical Gleason score & & & 0.089 \\ \hline
1, 6 (3 + 3) & 0 (0.0\%) & 14 (16.7\%) & \\ \hline
2, 7 (3 + 4) & 3 (15.0\%) & 26 (31.0\%) & \\ \hline
3, 7 (4 + 3) & 9 (45.0\%) & 26 (31.0\%) & \\ \hline
4, 8 & 4 (20.0\%) & 8 (9.5\%) & \\ \hline
5, 9–10 & 4 (20.0\%) & 10 (11.9\%) & \\ \hline tumor volume (mL.) & 11.0 (1.8–51.1) & 3.8 (0.3–74.2) & 0.002 \\ \hline Positive surgical margin & & & 0.027 \\ \hline Positive & 6 (30.0\%) & 49 (58.3\%) & \\ \hline Negative & 14 (70.0\%) & 35 (41.7\%) & \\ \hline Lymphovascular invasion & & & 0.020 \\ \hline Positive & 13 (65.0\%) & 74 (88.1\%) & \\ \hline Negative & 7 (35.0\%) & 10 (11.9\%) & \\ \hline Perineural invasion & & & 0.016 \\ \hline Positive & 2 (10.0\%) & 32 (38.1\%) & \\ \hline Negative & 18 (90.0\%) & 52 (61.9\%) & \\ \hline Extracapsular extension & & & 0.185 \\ \hline Positive & 11 (55.0\%) & 60 (71.4\%) & \\ \hline Negative & 9 (45.0\%) & 24 (28.6\%) & \\ \hline Seminal vessel invasion & & & 0.186 \\ \hline Positive & 15 (75.0\%) & 73 (86.9\%) & \\ \hline Negative & 5 (25.0\%) & 11 (33.1\%) & \\ \hline \end{tabular} Note. – Unless otherwise indicated, data are the number of patients, with percentages in parentheses. PSA = prostate-specific antigen. SUP = International Society of Unrological Pathology. MRI = Magnetic resonance image. PI-RADS = Prostate Imaging Reporting and Data System. \({}^{\ddagger}\) Data are median with the range in parentheses.  
\end{table} 
Table 1: Comparisons of clinical, imaging, and pathologic parameters between biochemical recurrence (BCR) and non-BCR groups.